Drug Profile


Alternative Names: Factor IX - Sangamo; SB-FIX

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Antihaemorrhagics; Gene therapies; Transcription factors; Zinc finger DNA binding proteins
  • Mechanism of Action Blood coagulation factor modulators; DNA binding protein modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haemophilia B

Most Recent Events

  • 28 Feb 2018 The Medicines and Healthcare Products Regulatory Agency approves Clinical Trial Authorisation application for SB-FIX in Haemophilia B (In adolescents, In adults)
  • 28 Feb 2018 Sangamo Therapeutics plans a phase I/II trial in Haemophilia B (In adolescents, In adults) in United Kingdom later in 2018
  • 04 May 2017 SB FIX receives Fast Track designation for Haemophilia B [Parenteral] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top